- 全部删除
您的购物车当前为空
Toripalimab是一种重组人源化免疫球蛋白G4(IgG4)单克隆抗体,特异性靶向并阻断程序性细胞死亡蛋白1(PD-1)免疫检查点受体,用于研究晚期或转移性恶性肿瘤和鼻咽癌。
Toripalimab是一种重组人源化免疫球蛋白G4(IgG4)单克隆抗体,特异性靶向并阻断程序性细胞死亡蛋白1(PD-1)免疫检查点受体,用于研究晚期或转移性恶性肿瘤和鼻咽癌。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 928 | In stock | |
| 5 mg | ¥ 2,320 | In stock | |
| 10 mg | ¥ 3,730 | In stock | |
| 25 mg | ¥ 5,930 | In stock |
Toripalimab 相关产品
| 产品描述 | Toripalimab is a recombinant, humanized immunoglobulin G4 (IgG4) monoclonal antibody that specifically targets and blocks the programmed cell death protein 1 (PD-1) immune checkpoint receptor, thereby acting as an immune checkpoint inhibitor used in clinical research for the investigation of advanced or metastatic malignancies, most notably nasopharyngeal carcinoma. |
| 体内活性 | 方法:Toripalimab(0.3-10 mg/kg,腹腔注射,每周两次, 6 次)处理敲入人PD-1的转基因小鼠品系,观察其对小鼠体内的肿瘤治疗效果。 |
| 别名 | 特瑞普利单抗 |
| CAS No. | 1924598-82-2 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容